Immunome Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Immunome Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Immunome Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$50.5M, a 990% decline year-over-year.
  • Immunome Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$317M, a 1301% decline year-over-year.
  • Immunome Inc. annual Operating Income (Loss) for 2023 was -$110M, a 197% decline from 2022.
  • Immunome Inc. annual Operating Income (Loss) for 2022 was -$36.9M, a 46.4% decline from 2021.
  • Immunome Inc. annual Operating Income (Loss) for 2021 was -$25.2M, a 106% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$110M -$72.6M -197% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$36.9M -$11.7M -46.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$25.2M -$12.9M -106% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$12.3M -$1.91M -18.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
2019 -$10.3M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.